Shilpa Medicare Wins SEC-CDSCO Approval for Nor-Ursodeoxycholic Acid Tablets Against NASH Shilpa Medicare has obtained regulatory approval for Nor-Ursodeoxycholic Acid tablets, a promising treatment for non-alcoholic fatty liver disease, paving the way for an upcoming market launch.

Shilpa Medicare Wins SEC-CDSCO Approval for Nor-Ursodeoxycholic Acid Tablets Against NASH #India #NASH #Shilpa_Medicare #Raichur #Nor_UDCA

Shilpa Medicare Introduces Nor-Ursodeoxycholic Acid for NASH Treatment Shilpa Medicare recently gained approval for Nor-Ursodeoxycholic Acid tablets, aiming to tackle non-alcoholic steatohepatitis with a market launch planned in India.

Shilpa Medicare Introduces Nor-Ursodeoxycholic Acid for NASH Treatment #India #NASH #Shilpa_Medicare #Raichur #Nor_UDCA